Madrigal Pharmaceuticals Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Madrigal Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Madrigal Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($3.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($3.58) by $0.14.
View Madrigal Pharmaceuticals' earnings history.

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MDGL stock has decreased by 1.1% and is now trading at $80.15.
View which stocks have been most impacted by COVID-19.

9 brokers have issued 12 month price targets for Madrigal Pharmaceuticals' stock. Their forecasts range from $111.00 to $204.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $172.13 in the next year. This suggests a possible upside of 114.8% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of MDGL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.32%), BlackRock Inc. (5.49%), State Street Corp (3.75%), Armistice Capital LLC (3.57%), Artisan Partners Limited Partnership (1.33%) and Citigroup Inc. (1.20%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals.

MDGL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, BlackRock Inc., Schonfeld Strategic Advisors LLC, Capital Impact Advisors LLC, FMR LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Madrigal Pharmaceuticals or view top insider-selling stocks.

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Citigroup Inc., Marshall Wace LLP, Marshall Wace LLP, Marshall Wace North America L.P., L1 Capital Pty Ltd, Vanguard Group Inc., and Maven Securities LTD.
View insider buying and selling activity for Madrigal Pharmaceuticals or or view top insider-buying stocks.

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $80.15.

Madrigal Pharmaceuticals has a market capitalization of $1.33 billion. The biopharmaceutical company earns $-202,240,000.00 in net income (profit) each year or ($13.09) on an earnings per share basis.

Madrigal Pharmaceuticals employs 42 workers across the globe.

Madrigal Pharmaceuticals was founded in 2011.

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263 or via email at [email protected]